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Abstract
Background: The current standard for Prostate Cancer (PCa) detection in biopsy-naïve men consists of 10–12
systematic biopsies under ultrasound guidance. This approach leads to underdiagnosis and undergrading of
significant PCa while insignificant PCa may be overdiagnosed. The recent developments in MRI and Contrast
Enhanced Ultrasound (CEUS) imaging have sparked an increasing interest in PCa imaging with the ultimate goal of
replacing these “blind” systematic biopsies with reliable imaging-based targeted biopsies.
Methods/design: In this trial, we evaluate and compare the PCa detection rates of multiparametric (mp)MRI-
targeted biopsies, CEUS-targeted biopsies and systematic biopsies under ultrasound guidance in the same patients.
After informed consent, 299 biopsy-naïve men will undergo mpMRI scanning and CEUS imaging 1 week prior to
the prostate biopsy procedure. During the biopsy procedure, a systematic transrectal 12-core biopsy will be
performed by one operator blinded for the imaging results and targeted biopsy procedure. Subsequently a
maximum of 4 CEUS-targeted biopsies and/or 4 mpMRI-targeted biopsies of predefined locations determined by an
expert CEUS reader using quantification techniques and an expert radiologist, respectively, will be taken by a
second operator using an MRI-US fusion device. The primary outcome is the detection rate of PCa (all grades) and
clinically significant PCa (defined as Gleason score ≥7) compared between the three biopsy protocols.
Discussion: This trial compares the detection rate of (clinically significant) PCa, between both traditional systematic
biopsies and targeted biopsies based on predefined regions of interest identified by two promising imaging
technologies. It follows published recommendations on study design for the evaluation of imaging guided prostate
biopsy techniques, minimizing bias and allowing data pooling. It is the first trial to combine mpMRI imaging and
advanced CEUS imaging with quantification.
Trial registration: The Dutch Central Committee on Research Involving Human Subjects registration number
NL52851.018.15, registered on 3 Nov 2015. Clinicaltrials.gov database registration number NCT02831920,
retrospectively registered on 5 July 2016.
Keywords: Prostate cancer, Prostate cancer imaging, mpMRI, CEUS, Contrast enhanced ultrasound, Targeted
prostate biopsies
* Correspondence: a.w.postema@amc.nl
1Department of Urology, AMC University Hospital, Amsterdam, The
Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Postema et al. BMC Urology  (2017) 17:27 
DOI 10.1186/s12894-017-0213-7
Background
The incidence of PCa has increased in the 1990’s, due to
increased awareness and prolific Prostate Specific Anti-
gen (PSA) screening. Although in the United States this
trend has partly reversed, PCa is still the most common
cancer in men representing 21% of cancer cases and it is
estimated that 180,890 men will be diagnosed with PCa
in United States in 2016 [1]. In Europe the incidence has
increased, with 417,00 new PCa diagnoses in 2012 [2].
According to current standards, patients with a clinical
suspicion of PCa based on elevated serum PSA and/or
digital rectal examination should undergo 10–12 sys-
tematic transrectal ultrasound (TRUS)-guided prostate
biopsies to confirm the diagnosis [3]. These systematic
“blind” prostate biopsies lead to a considerable rate of
overdiagnosis of clinically insignificant PCa as well as
underdiagnosis and undergrading of significant PCa [4].
Image - guided targeted biopsy approaches have been
proposed to address these problems [5]. Prostate cancer
imaging has thus far developed on two platforms: MRI
and Ultrasound. On the MRI platform, multiparametric
MRI(mpMRI) in which diffusion - weighted MRI and
dynamic contrast- enhanced MRI sequences are added
to anatomical T2-weighted imaging has become the
standard for PCa imaging [6]. A 2015 systematic review
on the accuracy of mpMRI for the detection of prostate
cancer found 12 studies and reported a negative predict-
ive value for the detection of clinically significant pros-
tate cancer between 63 and 98% and positive predictive
values of 34–68% [7]. However, these results should be
interpreted with caution since several used biopsy path-
ology as the reference standard to calculate sensitivity
and specificity. Several meta-analyses have addressed the
value of mpMRI - targeted biopsy cores and these show
an improved per-core detection rate and a beneficial
increased per-patient detection rate in patients with a
persistent clinical suspicion after prior negative biopsies
[5, 8]. The 2016 update of the EAU (European Associ-
ation of Urology) guidelines on PCa now recommends
performing mpMRI in these patients. However, at this
point, the value of using mpMRI and MRI-targeted
biopsies at initial biopsy in biopsy-naïve patient is
debated [3]. Even though high negative predictive values
for detecting significant prostate cancer have been
reported, significant disease can still be missed by MRI -
targeted biopsy. Furthermore, considerable heterogeneity
and risk of selection bias of published results exists. [8,
9]. The EAU guidelines therefore recommend combining
systematic and targeted biopsies [3]. The review by Van
Hove et al. shows a 1–43% absolute and 2–430% relative
increase in per-patient detection rate can be achieved by
adding mpMRI - targeted cores to systematic cores [9].
Several methods of using the information obtained by
mpMRI to target the region of interest with prostate
biopsies exist: in cognitive targeting, the operator makes
a visual estimation of where the MRI lesion is located
during a TRUS-guided biopsy procedure. Taking in-bore
biopsies during MRI scanning reduces the risk of target-
ing error but due to its magnet time consuming and
therefore costly nature, it is not used often. Fusion
devices have been developed that register the MRI im-
ages and US together, guiding the observer towards the
MRI lesion during the TRUS procedure [10, 11].
Prostate cancer may be visible on standard B-mode
TRUS. However, the sensitivity is generally reported to
be around 11–35% and the positive predictive value is
often cited to be between 17 and 57%, although some
studies have shown slightly better numbers [12, 13].
Hence, B-mode ultrasound is widely regarded as insuffi-
ciently accurate for tumor detection making systematic
ultrasound-guided biopsies necessary. A conclusion that
is supported by the guidelines [3, 14]. Contrast - En-
hanced Ultrasound (CEUS) has been proposed to
improve the accuracy of TRUS to detect Prostate Can-
cer. In CEUS, an intravascular Ultrasound Contrast
Agent (UCA) is used to visualize the changes in vascu-
larity that are typical for significant PCa, particularly
angiogenesis. It has been demonstrated that angiogenesis
is essential for prostate tumors to progress from small
indolent lesions below 2 mm in size to clinically signifi-
cant disease [15]. The UCA’s consist of gas-filled micro
bubbles of 1–10 μm with a lipid or protein shell that
have an intravascular lifespan of several minutes. A sys-
tematic review on CEUS demonstrated a sensitivity and
specificity of 70 and 74% or PCa detection. It must be
noted that this meta-analysis contains a mixture of
biopsy - controlled studies and prostatectomy - con-
trolled studies as well as different variants of CEUS. Of
particular interest is the analysis by van Hove et al. that
shows a 2–8% absolute or 7–35% relative increase in
per-patient detection rate was attained by adding CEUS
- targeted cores to systematic biopsy protocols [9]. This
analysis indicates improved per-patient detection rates
can be achieved with adding CEUS-targeted cores, how-
ever CEUS-targeted biopsy at this point cannot replace
systematic biopsy. Traditional drawbacks of CEUS are
its user-dependency, the limited number of planes that
can be visualized in one setting, and the fact that the
cues that signify a suspicious focus are subtle and
present in the image studies in a matter of seconds. To
overcome these drawbacks, computer-aided quantifica-
tion, a relatively new method to analyze CEUS record-
ings, is used to assist in the CEUS interpretation [16]. In
the present trial, we will use the Contrast Ultrasound
Dispersion Imaging (CUDI) method with computer-aided
quantification developed at the Eindhoven University of
Technology [17]. In short, this method entails const-
ructing per-pixel Time-Intensity-Curves (TICs) during the
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UCA inflow phase of CEUS recordings. Several parame-
ters calculated from the spatiotemporal distribution of
these TICs have shown very promising results in predict-
ing PCa presence with Area Under the Curve (AUC)
values reaching up to 0.88–0.89 [17, 18]. These results
were obtained by estimating how well CUDI could predict
whether pixels belonged to a benign or malignant region
of interest using radical prostatectomy specimens as the
reference standard. In the present study we will evaluate
the value of targeted biopsy procedures with mpMRI and
CEUS + CUDI quantitative imaging by performing both
procedures with systematic biopsies in the same patients
scheduled for initial prostate biopsies. This way we will be
able to determine how successful these tools can be used
for targeting biopsies and how these targeting procedures
compare to each other and to systematic biopsies. Add-
itionally, we will analyze to what extent the imaging tools
overlap in the tumors they detect or miss, and therefore to




– To compare the per-patient (significant) prostate
cancer detection rate for mpMRI-US fusion - tar-
geted biopsies and CEUS + CUDI-targeted biopsies
with 12-core systematic biopsies.
Secondary
– To evaluate the value of using both mpMRI and
CEUS + CUDI for targeted prostate biopsies.
Expected outcomes
Based on previous studies that used a fusion device to
take 2–4 mpMRI - targeted biopsy cores in biopsy naïve
patients, we expect a per-patient cancer detection rate
(CDR) between 40–54% for the mpMRI - targeted biop-
sies. With the targeted cores, CDRs were achieved that
were between 1% absolute higher and 13% absolute
lower than the CDRs of systematic biopsies in the same
series. Of note is that the biggest series used 3 different
methods of targeting the mpMRI cores: cognitive target-
ing, rigid fusion and elastic fusion. Their best result with
targeted cores relative to the systematic cores was
achieved with the elastic fusion method (33% CDR for
systematic cores and 47% for targeted cores). The
Artemis (Eigen, Grass Valley, USA) fusion system that
will be used in our trials uses elastic registration. The
majority of series have performed a similar analysis in
patients with previous negative systematic biopsies or
mixed patient cohorts which tend to show a better
performance of targeted cores relative to systematic
cores [19]. In our biopsy naïve cohort we expect to find a
per-patient CDR for all PCa grades that is in the same
range as the systematic biopsies. In contrast, we expect
the per-patient CDR for clinically significant (Gleason >3
+ 4) disease of the mpMRI - targeted biopsies to be
relatively higher compared to systematic biopsies.
Limited data is available for the value of CEUS-
targeted cores. Van Hove et al. reviewed 6 studies that
compared the CDRs for CEUS-targeted biopsies and
systematic biopsies [9]. They report that targeted biopsy
cores achieved CDRs between 13% absolute lower and
4% absolute higher than systematic cores in these
heterogeneous studies with mixed patient groups and
various CEUS variants used. None of the studies in this
review have included the use of quantitative techniques.
A previous study done in our own institution, that retro-
spectively correlated CEUS imaging with and without
quantification with systematic biopsy results, showed
improved significant PCa detection with the use of
quantification. In 82 patients, 5.6% of biopsy locations
that were classified benign on imaging showed clinically
significant disease when quantification software was
used, compared to 8.5% for CEUS without quantification
[20]. Unfortunately, no targeted biopsies were taken in
this retrospective analysis. We hypothesize that the
use of CUDI quantification software in our current
study will result in a CDR for significant disease up
to the level of systematic biopsies or better. To our
knowledge, there are no published data on the com-
plementarity of mpMRI and CEUS in prostate cancer
detection and biopsy targeting. Based on the available
data on the separate techniques, we expect that the
combination will result in a CDR higher than that of
systematic biopsies, especially for the detection of
clinically significant disease.
Study design
This study is a prospective in-vivo study in humans in
which we perform MRI imaging and CEUS imaging in
biopsy-naïve patients scheduled for prostate biopsies.
Targeted prostate biopsies based on these images will
be taken besides current standard of care systematic
biopsies. Since both imaging modalities and targeted
biopsies will be performed in the same patients, every
patient effectively serves as his own control. Patients
will undergo mpMRI imaging and CEUS imaging
approximately 1 week before the scheduled biopsy
appointment. During this week, MRI reading will be
performed by a specialized uroradiologist with ap-
proximately 10 years of prostate mpMRI experience
using the European Society of Urogenital Radiology
(ESUR) Prostate Imaging Reporting and Data System
standardised scoring system, version 2 (PIRADS v2)
[21]. The radiologist is blinded to CEUS and CUDI
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results. The CEUS recordings will be analysed using
the CUDI quantification technique. An observer expe-
rienced in CEUS of the prostate will read the CEUS
recordings and CUDI-maps, while blinded to the MRI
results. Before the biopsy procedure, the MRI - based
biopsy targets and CEUS + CUDI - based biopsy tar-
gets are therefore predetermined independently from
each other. During the biopsy session, approximately
1 week after the imaging is recorded, a physician who
is blinded to all imaging results and the targeted bi-
opsy procedure will first perform the standard 12-core
systematic biopsy to prevent potential bias by post-
biopsy haemorrhage seen on ultrasound after targeted
biopsies. Then a separate observer, using an MRI-US
fusion device, takes a maximum of 4 targeted biopsies
from the MRI lesions delineated by the radiologist
followed by a maximum of 4 targeted cores from the
CEUS + CUDI lesions identified by the CEUS expert.
Per-patient CDRs and tumor differentiation grades are
compared between each of the biopsy regimens: MRI -
targeted biopsies, CEUS + CUDI - targeted biopsies
and systematic biopsies.
Population
Two hundred ninety-nine biopsy-naïve men above the
age of 18 years that are scheduled for initial prostate
biopsies on the basis of a suspicious DRE and/or ele-
vated serum PSA (above 3 ng/ml) will be included in the
study. Patients will be recruited at the AMC University
Hospital and all study procedures will be performed at
that institution. Exclusion criteria are mostly related to
the MRI, the UCA used for CEUS imaging and biopsy
procedures(Table 1). Patients will be informed about
study procedures, risks and benefits, and are only in-
cluded after written informed consent has been
obtained.
Study procedures
Multiparametric magnetic resonance imaging
Prior to the mpMRI acquisition, a rectal preparation
with a laxative suppository (Bisacodyl) will be performed
and just before mpMRI scanning an anti-Peristaltic Drug
(Buscopan or Glucagon) will be given. mpMRI will be per-
formed in supine position on a 1.5 Tesla AVANTO® MRI
scanner (Siemens Healthcare, Erlangen, Germany) or on a
3 Tesla INGENIA® without endorectal coil (Philips Med-
ical Systems, Best, The Netherlands). The scanning proto-
col starts with T2-weighted sequences which will be
performed in sagittal, coronal and axial planes covering
the prostate and seminal vesicles. Then, a single-shot-
echo planar diffusion-weighted sequence with fat sup-
pression pulse is acquired and ADC maps are calculated.
Finally, dynamic contrast-enhanced images using
0.1 mmol of gadopentetate dimeglumine (Gadolinium
DTPA, Gadovist) per kg of body weight, are obtained.
More details on the mpMRI conduct can be found in
Table 2. mpMRI will be evaluated by a specialized
uroradiologist (blinded for CEUS results) on prostate
volume and area’s suspicious for PCa. Scoring of sus-
picion will be performed using PIRADS v2 [21]. All
lesions will be marked and delineated for MRI-TRUS
fusion using the ProFuse (Eigen, Grass Valley, USA)
software package that accompanies the Artemis fusion
device.
Contrast-enhanced ultrasound and quantification
Contrast Ultrasound scanning will be performed in the
left-lateral decubitus position using a Philips IU22 ultra-
sound scanner with a C10–3V endocavity probe (Philips
Healthcare, Bothell, USA) with power modulation at
3.5 MHz and a mechanical index (MI) of 0.06. A total of
four CEUS recordings will be made: from the base, mid-
base, mid apical and apical planes. The locations of these
planes within the prostate are stored using the Artemis
fusion device, for future targeting of suspicious lesions.
Each of the 2 min recordings will be started following the
administration of a 2.4 mL bolus of the contrast agent
SonoVue® (Bracco, Geneva, Switzerland) through an intra-
venous cannula. After each recording a pause of 3 min is
observed to allow sufficient UCA breakdown to assess
the inflow of the next UCA bolus. The CEUS recordings
are anonymized and transferred through a secure
connection to the Eindhoven University of Technology
for CUDI quantitative analysis. The CUDI maps are
Table 1 Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
1. Age ≥ 18 years
2. Signed informed consent
3. Referred for prostate mpMRI and prostate biopsies
1. Is incapable of understanding the language in which the information for the patient is given
2. Has undergone previous prostate biopsies
3. Active (urinary tract) infection or prostatitis
4. History of any clinically evidence of cardiac right-to-left shunts
5. Receives treatment that includes dobutamine
6. Severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) or uncontrolled
systemic hypertension or respiratory distress syndrome
7. Any medical condition or other circumstances which would significantly decrease the
chances of obtaining reliable data, achieving study objectives, or completing the study
8. Any (further) contraindication to undergo mpMRI or CEUS imaging
mpMRI multiparamteric Magentic Resonance Imaging, CEUS Contrast - Enhanced Ultrasound
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transferred back to the physicians to aid in the CEUS in-
terpretation and selection of the biopsy targets. This is
done by a CEUS expert, who is blinded to MRI results.
Biopsy procedure
Patients are prepared for the biopsy procedure with a
2 day course of fluoroquinolone prophylaxis. The biopsy
procedure is performed in the left-lateral decubitus pos-
ition using the same ultrasound device and probe as
used for the CEUS imaging. A first operator blinded to
the targeted biopsy procedure planning and imaging
results will take a standard 12-core systematic biopsy
that includes 2 medial and 4 laterally directed cores of
the peripheral zone of the prostate on each side. Then a
second physician, using the Artemis fusion device for
guidance, takes a maximum of 4 biopsies from targets
designated by the radiologist and a maximum of 4 biop-
sies from the targets designated by the CEUS expert.
The needle biopsy cores will be analysed for tumour
presence and grading by our institution’s specialized uro-
pathologist in accordance with current pathology
guidelines.
Sample size and statistical analysis
Statistical analysis
The per-patient PCa detection rates of both targeted
biopsy regimens will be tested separately for non-
inferiority against current standard 12-core systematic
biopsies using a one sided non-inferiority test for corre-
lated proportions [22, 23]. To evaluate if image- targeted
biopsies can be used complementarily, we will also
perform the same comparative analysis for the targeted
biopsy results combined, compared to the systematic
biopsies. Moreover, the per-patient CDR’s of all three
biopsy protocols will be directly compared using
McNemars test for correlated proportions. The same
analyses will be performed including all tumors and
including clinically significant tumors only, defined as
PCa with a Gleason score ≥3 + 4 = 7.
Sample size calculation
The sample size calculation is based on the non-inferiority
test between the targeted biopsy procedures and the
systematic biopsies. For this test we performed a power
analysis, with the detection rate for systematic biopsies set
at 45% [24], a power of 80% and the significance level
(alpha) of 5%. The maximum allowable difference in
detection rate for the targeted biopsies to be considered
non-inferior to systematic biopsies was set at 1%. We
expect a maximum proportion of discordant pairs of 15%
and a detection rate difference of 5%. The required sample
size according to these specifications is 260 patients. Based
on the estimation that 15% of the patients that are sched-
uled for biopsies will not receive targeted biopsies due to
the absence of PCa suspected lesions on imaging; a total
number of 299 patients will be enrolled in the study.
Literature shows that of all positive biopsies about 25%
is Gleason >6 [25–27]. Results from our institution differ
from literature as only 40% of all the patients with PCa
at biopsy have a Gleason score 6 PCa, while 60% of them
have a Gleason score >6 PCa. Thus, numbers of positive
biopsies and Gleason score > 6 are higher than reported
in literature. Based on our historical data we expect that
by including 299 patients in the study we will find ~65
cases with a Gleason score = 6 and ~100 cases with a
Gleason score > 6. For differentiation between Gleason
score we hypothesize that we need at least 40 people in
both Gleason grade groups.
Table 2 MRI conduct
mpMRI Conduct
Unit Philips 3 Tesla INGENIA® Siemens 1.5 Tesla AVANTO®
Slice Thickness
T2-Weighted 3 mm 3 mm
DW-MRI 4 mm 5 mm
DCE-MRI 2 mm 4 mm
T2-weighted planes axial, coronal and sagittal axial, coronal and sagittal
DCE-MRI
Temporal resolution 5.00 s 3.06 s
Post-processing model Tofts model using Dynacad (In Vivo, Best, The Netherlands) Tofts model using Dynacad (In Vivo, Best, The Netherlands)
DW-MRI,
B-values, B0, B100, B1000 B50, B800
Imaging sets ADC, calculated B1500 ADC
Quantitative analysis primarily qualitative, quantitative in unclear cases primarily qualitative, quantitative in unclear cases
mpMRI multiparamteric Magentic Resonance Imaging, DW-MRI Diffusion - Weighted Magnetic Resonance Imaging, DCE-MRI Dynamic Contrast- Enhanced Magnetic
Resonance Imaging
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Quality and patient safety
The quality of the data obtained and patient safety will
be continuously monitored by the investigators. Period-
ical (yearly) reporting of study progression and patient
safety will be performed to the reviewing Institutional
Review Board (IRB). In accordance to section 10, subsec-
tion 4, of the Wet Medisch-Wetenschappelijk Onderzoek
met Mensen (Medical Research Involving Human Sub-
jects Act), the investigators will suspend the study if there
is sufficient ground that continuation of the study will
jeopardise subject health or safety. The investigators will
notify the accredited IRB without undue delay of a
temporary halt including the reason for such an action.
The study will be suspended pending a further positive
decision by the accredited IRB. The investigator will take
care that all subjects are kept informed.
Risks and benefits
The mpMRI and TRUS - guided prostate biopsies are
already performed routinely in our institution. The extra
targeted prostate biopsies are considered to convey min-
imal additional risk over the systematic biopsy cores that
were already planned. When contraindications for
mpMRI and necessary preparations for prostate biopsies
(proper antibiotic prophylaxis and management of anti-
coagulant medications) are followed, these investigations
are considered safe [3]. After use in thousands of
patients, adverse events related to micro bubble UCA’s
appear to be transient, mild and rare [28–30]. The most
frequent minor side-effects are a transient alteration of
taste, local pain at the injection site and facial or general
flush (1–5%) [31]. Serious adverse events, which consists
of hypersensitivity allergic reactions, are rare (<0.01%)
[32]. In a study with SonoVue® in patients with chronic
obstructive pulmonary disease, CEUS appeared to be as
safe and well tolerated as in a healthy control group
[28]. The Committee for Medicinal Products for Human
Use has granted SonoVue® a marketing authorization,
but it should not be used together with the medicine
dobutamine and in pregnant or breastfeeding women
(http://www.ema.europa.eu). Although patients are in-
formed about the experimental nature of CEUS imaging,
a potential benefit of participation is the real possibility
of finding (significant) PCa in one of the targeted biop-
sies that would otherwise have remained undetected.
Discussion
Improvement of the PCa diagnostic pathway is neces-
sary, and will likely depend on the advances in PCa
imaging. Multiparametric MRI has a recognized value
before a second biopsy in case of a persistent clinical
suspicion for PCa. The value in biopsy - naïve patients
and the possibility to omit systematic biopsies is debated
[3]. Contrast -enhanced ultrasound has shown promising
results, but should currently be viewed as experimental.
This trial will provide data on both these techniques,
allowing comparison and assessment of complementar-
ity. The study design chosen is in line with recommen-
dations formulated by the Standards of reporting for
MRI-targeted biopsy studies (START) Working Group
[33] and by van Hove et al [9]. To validate imaging -
targeted prostate biopsy protocols van Hove et al.
recommend using either one of two study designs:
randomize patients to undergo either systematic biopsies
alone or systematic biopsies and targeted biopsies. In the
other option every patient undergoes both targeted
biopsies and systematic biopsies by separate blinded ob-
servers. In our study design all patients undergo both
imaging procedures and both targeted and systematic
biopsies. The targeted biopsies and systematic biopsies
are performed by separate observers. The targeted bi-
opsy locations are predetermined by blinded readers and
targeted through a fusion device. To prevent potential
bias by post-biopsy haemorrhage seen on ultrasound the
targeted biopsies are performed after the systematic
biopsies. This way we prevent information gathered
from one imaging technique to influence biopsy target-
ing for the other imaging technique. In both study
designs the (significant) PCa detection rates are com-
pared. An advantage of using these study designs is that
there is no spectrum bias, i.e. the relevant biopsy popu-
lation is being studied. Also, there is no observer bias,
the investigator reading the images does not already
know that there must be a tumor. Both spectrum bias
and observer bias occur when translating results
obtained from the correlation of imaging and radical
prostatectomy specimens towards the primary diagnostic
setting. Furthermore, the endpoint in this study design,
(significant) PCa detection, is the most relevant endpoint
in the clinic. We therefore believe that our trial will
provide important and necessary data on one of the
most relevant topics in PCa care. This data is gathered
in a recommended, standardized fashion to minimize
bias and allow data pooling.
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